Diplopia and HMG-CoA reductase inhibitors

F. W. Fraunfelder; F. T. Fraunfelder; Ralph Edwards

doi:10.3109/15569529909065546

Diplopia and HMG-CoA reductase inhibitors

F. W. Fraunfelder, F. T. Fraunfelder, Ralph Edwards

Ophthalmology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Seventy-one cases of possible diplopia associated with cholesterol- lowering, HMG-CoA reductase inhibitors lovastatin, simvastatin, pravastatin, or fluvastatin are reviewed. Cases were received from spontaneous reporting systems, and while these data are incomplete, two cases recurred on rechallenge and 31 had positive dechallenge tests. This suggests that these agents may cause diplopia in some patients. Diplopia may be a potential marker of these agents' drug-induced, generalized muscle dysfunction.

Original language	English (US)
Pages (from-to)	287-289
Number of pages	3
Journal	Journal of Toxicology - Cutaneous and Ocular Toxicology
Volume	18
Issue number	4
DOIs	https://doi.org/10.3109/15569529909065546
State	Published - Jan 1 1999

ASJC Scopus subject areas

Ophthalmology
Toxicology
Health, Toxicology and Mutagenesis

Access to Document

10.3109/15569529909065546

Fingerprint Dive into the research topics of 'Diplopia and HMG-CoA reductase inhibitors'. Together they form a unique fingerprint.

Cite this

@article{8c2f412efeca443c9ebb5e2e96fa3a5c,

title = "Diplopia and HMG-CoA reductase inhibitors",

abstract = "Seventy-one cases of possible diplopia associated with cholesterol- lowering, HMG-CoA reductase inhibitors lovastatin, simvastatin, pravastatin, or fluvastatin are reviewed. Cases were received from spontaneous reporting systems, and while these data are incomplete, two cases recurred on rechallenge and 31 had positive dechallenge tests. This suggests that these agents may cause diplopia in some patients. Diplopia may be a potential marker of these agents' drug-induced, generalized muscle dysfunction.",

author = "Fraunfelder, {F. W.} and Fraunfelder, {F. T.} and Ralph Edwards",

year = "1999",

month = jan,

day = "1",

doi = "10.3109/15569529909065546",

language = "English (US)",

volume = "18",

pages = "287--289",

journal = "Cutaneous and Ocular Toxicology",

issn = "1556-9527",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Diplopia and HMG-CoA reductase inhibitors

AU - Fraunfelder, F. W.

AU - Fraunfelder, F. T.

AU - Edwards, Ralph

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Seventy-one cases of possible diplopia associated with cholesterol- lowering, HMG-CoA reductase inhibitors lovastatin, simvastatin, pravastatin, or fluvastatin are reviewed. Cases were received from spontaneous reporting systems, and while these data are incomplete, two cases recurred on rechallenge and 31 had positive dechallenge tests. This suggests that these agents may cause diplopia in some patients. Diplopia may be a potential marker of these agents' drug-induced, generalized muscle dysfunction.

AB - Seventy-one cases of possible diplopia associated with cholesterol- lowering, HMG-CoA reductase inhibitors lovastatin, simvastatin, pravastatin, or fluvastatin are reviewed. Cases were received from spontaneous reporting systems, and while these data are incomplete, two cases recurred on rechallenge and 31 had positive dechallenge tests. This suggests that these agents may cause diplopia in some patients. Diplopia may be a potential marker of these agents' drug-induced, generalized muscle dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0032736732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032736732&partnerID=8YFLogxK

U2 - 10.3109/15569529909065546

DO - 10.3109/15569529909065546

M3 - Article

AN - SCOPUS:0032736732

VL - 18

SP - 287

EP - 289

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

IS - 4

ER -